Curated News
By: NewsRamp Editorial Staff
March 20, 2025
SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor for Multiple Diseases at RIS and ATS Conference
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- SignaBlok, Inc. announced positive preclinical data on macrophage-restricted TREM-1 inhibitor, showcasing potential market advantage.
- SignaBlok's SCHOOL technology platform supports clinical development of TREM-1 drug with minimal risk of failure due to new mechanism of action.
- SignaBlok's innovative therapies offer hope for treating inflammation-associated diseases, potentially saving lives and improving patient outcomes.
- TREM-1 blockade by SignaBlok protects against sepsis, reduces lung inflammation, and reverses fibrosis, demonstrating promising advancements in medical research.
Impact - Why it Matters
This news matters as SignaBlok's innovative peptide therapy shows promise in treating severe inflammatory conditions. The potential of their technology platform to develop effective treatments with minimal risk of failure could revolutionize the approach to diseases like sepsis, ARDS, and PF, impacting patient outcomes and healthcare costs.
Summary
SignaBlok, Inc., a biotechnology company, announced positive preclinical data on its macrophage-restricted TREM-1 inhibitor for sepsis, ARDS, and PF at the RIS and ATS Conference. The data showed protection from death in septic animals, reduced lung inflammation in rats, and reversal of fibrosis in mice. The company's SCHOOL technology platform supports the drug's clinical development.
Source Statement
This curated news summary relied on this press release disributed by 24-7 Press Release. Read the source press release here, SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor for Multiple Diseases at RIS and ATS Conference
